Medical AI Alliance
← Company Index
Pharma & CDMOKOSDAQ 200670110 approvals2 trials

Humedix Co., Ltd.

Official website

KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.

As of 2026-10-10, Humedix Co., Ltd. has 31 Korean MFDS device approvals, 79 Korean MFDS drug approvals, 3 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2003 and listed on KOSDAQ in 2014, Humedix is a hyaluronic-acid-based aesthetics and CMO company. Its aesthetics division supplies the Elravie Premier and Revolax fillers, Leedstox botulinum toxin, Elravie Cosmetic skincare, and the Dermashine/Dermacne medical devices, while its CMO division manufactures arthritis treatments such as Hyhial Once, Hyhial Plus, and Hyhial injections, Prosan eye drops, and HA/PDRN/sodium-heparin raw pharmaceutical ingredients. It develops new products by combining previously approved active pharmaceutical ingredients (APIs) with biocompatible-polymer drug delivery technologies based on hyaluronic acid, PDRN, and PEG, and operates under approval standards including China's NMPA, Brazil's Anvisa, Europe's EMA, and the US FDA.

Products & technology

  • Elravie Premier (filler)Aesthetic dermal filler
  • Revolax (filler)Aesthetic dermal filler
  • Leedstox (botulinum toxin)Aesthetic botulinum toxin
  • Hyhial Once/Plus/injectionArthritis treatment
  • Prosan eye dropsOphthalmic eye-drop treatment

Regulatory approvals

data.go.kr

79 Korean MFDS drug approvals · 1996–2026 / 31 Korean MFDS device approvals · 2011–2026

  • MFDSGraft/prosthesis, biomaterial2026-04-24
    Product approval · Class 4제허 26-314 호
  • MFDSGraft/prosthesis, biomaterial2026-04-24
    Product approval · Class 4제허 26-313 호
  • MFDSGraft/prosthesis, biomaterial2026-04-22
    Product approval · Class 4제허 26-307 호
  • MFDS drugHufresh Eye drops 0.5%(Carboxymethylcellulose Sodium)(Single-dose)2026-04-02
    Drug · OTC · Notification202600945
  • MFDS drugHUAREN Eye Drops(Polydeoxyribonucelotide sodium)(Single-dose)2025-12-02
    Drug · OTC · Notification202503143
  • MFDSGraft/prosthesis, biomaterial2025-09-09
    Product approval · Class 4제허 25-618 호
  • MFDS drugCGcough Tab.2025-05-09
    Drug · Prescription · Approval202501136
  • MFDS drugGado-Q prefilled Inj.2025-03-26
    Drug · Prescription · Approval202500703
  • MFDS drugOlifit Inj.2024-12-11
    Drug · Prescription · Approval202402922
  • MFDS drughuga inj2024-07-12
    Drug · Prescription · Approval202401724
  • MFDSDressing, fluid-impermeable film2024-06-04
    Product approval · Class 2제인 24-554 호
  • MFDS drugHufresh Eye drops 1%(Carboxymethylcellulose Sodium)(Single-dose)2023-04-20
    Drug · OTC · Notification202301298
Show 68 more
  • MFDSGraft/prosthesis, biomaterial2022-07-06
    Product approval · Class 4제허 22-434 호
  • MFDS drugHuequa-S Eye Drops (single use)2022-06-20
    Drug · Prescription · Approval202202568
  • MFDSGraft/prosthesis, biomaterial2022-01-19
    Product approval · Class 4제허 22-37 호
  • MFDSGraft/prosthesis, biomaterial2021-11-02
    Product approval · Class 4제허 21-878 호
  • MFDSGraft/prosthesis, biomaterial2021-09-16
    Product approval · Class 4제허 21-776 호
  • MFDSDressing, fluid-impermeable film2021-04-28
    Product approval · Class 2제인 21-4359 호
  • MFDSDressing, fluid-impermeable film2021-04-27
    Product approval · Class 2제인 21-4354 호
  • MFDS drugHudaxin Inj.(Thymosin alpha-1)2021-04-19
    Drug · Prescription · Approval202103184
  • MFDS drugVivitoxin Inj. 100unit(Clostridium Botulinum Toxin Type A)2021-03-11
    Drug · Prescription · Approval202102247
  • MFDS drugHumetov Film coated Tab. 10/10mgRevoked2021-02-18
    Drug · Prescription · Approval202101576
  • MFDS drugHumetov Film coated Tab. 10/20mgRevoked2021-02-18
    Drug · Prescription · Approval202101577
  • MFDS drugHumetov Film coated Tab. 10/40mgRevoked2021-02-18
    Drug · Prescription · Approval202101578
  • MFDSGraft/prosthesis, biomaterial2020-10-08
    Product approval · Class 4제허 20-867 호
  • MFDSDressing, fluid-impermeable film2020-08-19
    Product approval · Class 2제인 20-4768 호
  • MFDS drugHumedix Sterilized Water for Injection2020-05-28
    Drug · Prescription · Notification202004005
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological methodRevoked2020-05-18
    Product approval · Class 3체외 제허 20-368 호
  • MFDSGraft/prosthesis, biomaterial2020-03-23
    Product approval · Class 4제허 20-206 호
  • MFDS drugHubandron Inj.(Ibandronate Sodium Monohydrate)2020-01-29
    Drug · Prescription · Notification202000457
  • MFDSGraft/prosthesis, biomaterial2020-01-03
    Product approval · Class 4제허 20-9 호
  • MFDS drugHutadine Eye Drops 0.1%(Olopatadine Hydrochloride)2019-11-07
    Drug · Prescription · Approval201907808
  • MFDS drugHupixaban Tab. 2.5mg(Apixaban)2019-10-15
    Drug · Prescription · Approval201907267
  • MFDS drugHupixaban Tab. 5mg(Apixaban)2019-10-15
    Drug · Prescription · Approval201907268
  • MFDS drugIbufen Inj.(Ibuprofen)2019-07-18
    Drug · Prescription · Notification201904810
  • MFDS drugPiosin Tab. 15mg2019-03-19
    Drug · Prescription · Approval201901673
  • MFDS drugHumia Inj.(BDDE bridged Sodium Hyaluronate Gel)2019-03-08
    Drug · Prescription · Approval201901449
  • MFDS drugDonerin Tab. 10mg (donepezil HCl)2019-02-14
    Drug · Prescription · Approval201900918
  • MFDS drugDonerin Tab. 5mg (donepezil HCl)2019-02-14
    Drug · Prescription · Approval201900923
  • MFDS drugHulecin Eye Drops(Levofloxacin)2019-01-31
    Drug · Prescription · Notification201900775
  • MFDS drugHuclo Eye Drops(Diclofenac Sodium)2019-01-30
    Drug · Prescription · Notification201900709
  • MFDS drugHutomycin Eye Drops(Tobramycin)2019-01-30
    Drug · Prescription · Notification201900726
  • MFDS drugHuflox Eye Drops(Ofloxacin)2019-01-14
    Drug · Prescription · Notification201900158
  • MFDSGraft/prosthesis, biomaterial2019-01-08
    Product approval · Class 4제허 19-21 호
  • MFDS drugHumetholone-T Eye Drops2018-12-21
    Drug · Prescription · Notification201805225
  • MFDS drugHemetholone Eye Drops(Fluorometholone)2018-12-20
    Drug · Prescription · Notification201805186
  • MFDS drugHutofen Eye Drops(Ketotifen Fumarate)2018-12-10
    Drug · OTC · Notification201804962
  • MFDSGel for medical use, non-sterilized2018-07-30
    Product approval · Class 1제신 18-964 호
  • MFDS drugRevitalex Inj.(Polydeoxyribonucleotide Sodium)2018-04-11
    Drug · Prescription · Notification201801563
  • MFDS drugRevitalex Pre-filled Inj.(Polydeoxyribonucleotide Sodium)2018-04-11
    Drug · Prescription · Notification201801564
  • MFDS drugProsn 0.3% Eye Drops(Sodium Hyaluronate)(Single-dose)2018-01-09
    Drug · Prescription · Notification201800137
  • MFDSGraft/prosthesis, biomaterial2017-12-13
    Product approval · Class 4제허 17-941 호
  • MFDSGraft/prosthesis, biomaterial2017-12-13
    Product approval · Class 4제허 17-940 호
  • MFDS drugEivasta Tab. 10/160mg2017-07-26
    Drug · Prescription · Approval201706190
  • MFDS drugEivasta Tab. 5/80mg2017-07-24
    Drug · Prescription · Approval201706139
  • MFDS drugEivasta Tab. 5/160mg2017-07-14
    Drug · Prescription · Approval201705678
  • MFDS drugMontestal tab. 10mg (monteleukast)2017-04-24
    Drug · Prescription · Approval201702073
  • MFDS drugEitista Tab. 80/5mg2017-02-06
    Drug · Prescription · Approval201700616
  • MFDS drugEitista Tab. 40/5mg2017-02-06
    Drug · Prescription · Approval201700618
  • MFDSGraft/prosthesis, biomaterial2017-01-24
    Product approval · Class 4제허 17-73 호
  • MFDS drugHumedix Glutathione Inj. 600mg(Glutathione(Reduced))(for export)2016-12-30
    Drug · Prescription · Notification201607404
  • MFDS drugHumedix Glutathione Inj. 1200mg(Glutathione(Reduced))(for export)2016-12-28
    Drug · Prescription · Notification201607343
  • MFDS drugHusop-S Eye Drops(single use)(for export)2016-11-18
    Drug · Prescription · Notification201606673
  • MFDS drugHuniz Tiropramide HCI Tablet2015-05-27
    Drug · Prescription · Approval201503193
  • MFDS drugHuniz Aceclofenac Tablet2015-05-14
    Drug · Prescription · Approval201502927
  • MFDS drugHuniz Nizatidine Capsule 150mg2015-04-28
    Drug · Prescription · Approval201502541
  • MFDS drugHuniz Clopidogrel Bisulfate Tablet2015-04-23
    Drug · Prescription · Approval201502401
  • MFDSGraft/prosthesis, biomaterial2015-03-16
    Product approval · Class 4제허 15-362 호
  • MFDS drugSerocob cap. 200mg (celecoxib)2014-12-23
    Drug · Prescription · Approval201406030
  • MFDS drugProsan 0.15% Eye Drops(Sodium Hyaluronate)(Single-dose)2014-12-04
    Drug · Prescription · Notification201405740
  • MFDS drugHigh Hyal Plus Inj.2%(Sodium Hyaluronate)2014-07-07
    Drug · Prescription · Approval201402999
  • MFDSGraft/prosthesis, biomaterial2014-04-09
    Product approval · Class 4제허 14-830 호
  • MFDS drugKerocid Tab. (loxoprofen Na)2013-07-23
    Drug · Prescription · Approval201308352
  • MFDS drugFlucan Capsule 50mg(Fluconazole)2013-03-20
    Drug · Prescription · Approval201306321
  • MFDS drugRabena Tab. 10mg (rabeprazole)2012-11-15
    Drug · Prescription · Approval201208286
  • MFDS drugFreestar Tab. 5mg(Finasteride)2012-10-31
    Drug · Prescription · Approval201207578
  • MFDSGraft/prosthesis, biomaterial2012-09-10
    Product approval · Class 4제허 12-1158 호
  • MFDS drugHuclor cap.(Cefaclor Hydrate)2012-08-27
    Drug · Prescription · Approval201206594
  • MFDSNasal splint, external2012-07-13
    Product approval · Class 1대전 제신 12-46 호
  • MFDSGraft/prosthesis, biomaterial2012-01-25
    Product approval · Class 4제허 12-108 호

Showing the 80 most recent of 110 records.

Clinical trials

data.go.kr

2 MFDS clinical trial authorisations · 2021–2024 (Phase 3 1 · Bioequivalence 1)

  • Phase 3프로산0.3%점안액(히알루론산나트륨)(1회용)2024-05-20

    1 trial site

  • Bioequivalence휴클러캡슐(HMC3-077)2021-10-20

    2 trial sites

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

API-생체적합성 고분자(HA·PDRN·PEG) 융복합 DDS 개발전략 · Combines previously approved APIs with drug delivery technology to improve durability, reduce side effects, and develop new indications, under a Low-Cost-High-Effectiveness strategy

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 56 more patents

AI reads

MAA server logs · IP-verified
136
Times AI engines pulled Humedix Co., Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

1
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

135
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

11
live 0
Last 7 days
104
live 1
Last 30 days
136
live 1
All time
  • OpenAIChatGPT-Userlive1
  • OpenAIOAI-SearchBot117
  • GoogleGoogleOther12
  • PerplexityPerplexityBot3
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 10, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Humedix Co., Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsPharma & CDMO

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

DongKookPharmaceuticalCo.,Ltd.5 shared

KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.

HANS BIOMED CORPORATION4 shared

KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.

PharmaResearch Co., Ltd.4 shared

KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.

WonIk Co.,LTD3 shared

WonIk, founded in 1983 and KOSDAQ-listed in 1997, operates pressure sensor, dermo-cosmetic, and medical device distribution businesses.

HUONS CO., LTD.3 shared

KOSDAQ-listed pharmaceutical and healthcare company producing lidocaine anesthetics and the Kynix hyaluronic-acid eye-drop line.

DongBang Medical Co., Ltd.3 shared

KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.

Chabiotech Co.,Ltd.3 shared

Cord blood storage and cell therapy company that has expanded into global CDMO manufacturing and overseas medical network services.

JETEMA Co.,Ltd.3 shared

Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.

BNC KOREA, Inc.3 shared

Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.

CAREGEN CO.,LTD.3 shared

CAREGEN develops peptide-based cosmeceuticals sold in 130 countries and ophthalmic drug candidates CG-P5 and CG-T1.

BioPlus Co., Ltd2 shared

Founded in 2003 and KOSDAQ-listed in 2021, BioPlus develops HA-based bio medical devices and biopharmaceuticals using its proprietary MDM Technology platform.

DONGWHA PHARM.CO.,LTD2 shared

Dongwha Pharm, founded in 1897 and KOSPI-listed in 1976, is a diversified company centered on pharmaceuticals.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition